Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
000020.KS
Top 10 Correlated ETFs
000020.KS
Top 10 Correlated Stocks
000020.KS
Financial details
Company Rating
Buy
Market Cap
243.02B
Income
17.41B
Revenue
317.9B
Book val./share
12663.8
Cash/share
4128.75
Dividend
180
Dividend %
2.18%
Employees
736
Optionable
No
Shortable
Yes
Earnings
-
P/E
13.15
Forward P/E
-
PEG
-1.95
P/S
0.72
P/B
0.65
P/C
2.03
P/FCF
12.4
Quick Ratio
1.55
Current Ratio
3.05
Debt / Equity
0.02
LT Debt / Equity
0.02
-
-
EPS (TTM)
337.04
EPS next Y
-
EPS next Q
-
EPS this Y
-44.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.67%
Revenue last 5Y
2.51%
Revenue Q/Q
2.26%
EPS Q/Q
336.01%
-
-
-
-
SMA20
-13.83%
SMA50
-20.27%
SMA100
-30.77%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
5%
ROC
0.08%
Gross Margin
52%
Oper. Margin
9%
Profit Margin
5%
Payout
29%
Shs Outstand
27.68M
Shs Float
19.18M
-
-
-
-
Target Price
-
52W Range
8770.0-21550.0
52W High
-61.02%
52W Low
-4.22%
RSI
28.47
Rel Volume
0.71
Avg Volume
106.22K
Volume
75.12K
Perf Week
-7.49%
Perf Month
-21.13%
Perf Quarter
-36.12%
Perf Half Y
-38.91%
-
-
-
-
Beta
1.52036
-
-
Volatility
344.46%, 645.6%
Prev Close
2.82%
Price
8400
Change
2.82%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 9.36K | 11.11K | 11.13K | 9.86K | 9.32K | |
| Net income per share | 1.7K | 364.7 | 340.57 | 1.03K | 568.63 | |
| Operating cash flow per share | -597.56 | -157.93 | 481.2 | 1.89K | 1.15K | |
| Free cash flow per share | -719.47 | -292 | 281.77 | 800.99 | 358.19 | |
| Cash per share | 4.69K | 3.76K | 4.35K | 4.36K | 3.87K | |
| Book value per share | 10.74K | 10.76K | 10.9K | 12K | 11.04K | |
| Tangible book value per share | 10.52K | 10.57K | 10.7K | 11.8K | 10.88K | |
| Share holders equity per share | 10.74K | 10.76K | 10.9K | 12K | 11.04K | |
| Interest debt per share | 0 | 0 | 257.76 | 578.86 | 377.29 | |
| Market cap | 298.57B | 265.86B | 220.86B | 415.5B | 367.7B | |
| Enterprise value | 266.99B | 225.25B | 189.99B | 372.59B | 318.69B | |
| P/E ratio | 6.35 | 26.41 | 23.49 | 14.57 | 20.58 | |
| Price to sales ratio | 1.15 | 0.87 | 0.72 | 1.53 | 1.25 | |
| POCF ratio | -18.07 | -60.98 | 16.62 | 7.96 | 10.21 | |
| PFCF ratio | -15.01 | -32.98 | 28.39 | 18.79 | 32.66 | |
| P/B Ratio | 1.01 | 0.89 | 0.73 | 1.25 | 1.06 | |
| PTB ratio | 1.01 | 0.89 | 0.73 | 1.25 | 1.06 | |
| EV to sales | 1.03 | 0.73 | 0.62 | 1.37 | 1.09 | |
| Enterprise value over EBITDA | 3.48 | 8.7 | 6.71 | 8.39 | 8.55 | |
| EV to operating cash flow | -16.16 | -51.66 | 14.3 | 7.13 | 8.84 | |
| EV to free cash flow | -13.42 | -27.94 | 24.42 | 16.85 | 28.31 | |
| Earnings yield | 0.16 | 0.04 | 0.04 | 0.07 | 0.05 | |
| Free cash flow yield | -0.07 | -0.03 | 0.04 | 0.05 | 0.03 | |
| Debt to equity | 0 | 0 | 0.02 | 0.01 | 0.01 | |
| Debt to assets | 0.19 | 0.2 | 0.2 | 0.21 | 0.2 | |
| Net debt to EBITDA | -0.41 | -1.57 | -1.09 | -0.97 | -1.31 | |
| Current ratio | 3.86 | 3.75 | 4.23 | 3.3 | 3.31 | |
| Interest coverage | 0 | 0 | 47.92 | 79.26 | 58.72 | |
| Income quality | -0.35 | -0.43 | 1.41 | 1.83 | 2.02 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Payout ratio | 0.06 | 0.41 | 0.35 | 0.12 | 0.28 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.01 | 0.04 | 0.04 | |
| Capex to operating cash flow | 0.2 | 0.85 | -0.41 | -0.58 | -0.69 | |
| Capex to revenue | -0.01 | -0.01 | -0.02 | -0.11 | -0.08 | |
| Capex to depreciation | -0.29 | -0.33 | -0.48 | -2.81 | -2.05 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 20.27K | 9.4K | 9.14K | 16.7K | 11.88K | |
| ROIC | 0.04 | 0.04 | 0.03 | 0.06 | 0.06 | |
| Return on tangible assets | 0.13 | 0.03 | 0.03 | 0.07 | 0.04 | |
| Graham Net | 2.81K | 1.9K | 2.23K | 1.77K | 1.65K | |
| Working capital | 173.78B | 167.09B | 179.74B | 155.25B | 153.74B | |
| Tangible asset value | 290.81B | 291.82B | 295.41B | 325.71B | 342B | |
| Net current asset value | 164.22B | 154.69B | 160.3B | 131.62B | 132.53B | |
| Invested capital | 0 | 0 | 0.02 | 0.05 | 0.03 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 20.15B | 24.24B | 17.92B | 18.52B | 17.82B | |
| Average inventory | 38.06B | 41.61B | 36.47B | 39.5B | 37.87B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 52.71 | 57.35 | 34.1 | 50.68 | 43.49 | |
| Days of inventory on hand | 88.6 | 83.68 | 65.81 | 108.08 | 92.08 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 6.92 | 6.36 | 10.7 | 7.2 | 8.39 | |
| Inventory turnover | 4.12 | 4.36 | 5.55 | 3.38 | 3.96 | |
| ROE | 0.16 | 0.03 | 0.03 | 0.09 | 0.05 | |
| Capex per share | -121.91 | -134.07 | -199.43 | -1.09K | -788.3 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.75K | 2.47K | 725.34 | 810.66 | 3.15K | |
| Net income per share | 226.98 | 16 | 54.27 | 49.77 | 217 | |
| Operating cash flow per share | 228.09 | 171.29 | 152.6 | 157.51 | 172.93 | |
| Free cash flow per share | -88 | -189.98 | 110.2 | 104.31 | 43.29 | |
| Cash per share | 4.27K | 3.99K | 1.15K | 1.17K | 4.13K | |
| Book value per share | 12.27K | 12.18K | 3.3K | 3.29K | 12.66K | |
| Tangible book value per share | 12.04K | 11.97K | 3.25K | 3.25K | 12.46K | |
| Share holders equity per share | 12.27K | 12.18K | 3.3K | 3.29K | 12.66K | |
| Interest debt per share | 472.06 | 452.8 | 109.84 | 109.05 | 435.78 | |
| Market cap | 432.06B | 498.85B | 1536.15B | 1436.2B | 268.64B | |
| Enterprise value | 406.06B | 470.62B | 1487.15B | 1372.6B | 232.11B | |
| P/E ratio | 17.24 | 278.91 | 67.26 | 68.56 | 11.16 | |
| Price to sales ratio | 5.7 | 7.22 | 20.13 | 16.84 | 3.08 | |
| POCF ratio | 68.61 | 104.21 | 95.67 | 86.66 | 56.03 | |
| PFCF ratio | -177.84 | -93.96 | 132.49 | 130.86 | 223.82 | |
| P/B Ratio | 1.28 | 1.47 | 4.43 | 4.14 | 0.77 | |
| PTB ratio | 1.28 | 1.47 | 4.43 | 4.14 | 0.77 | |
| EV to sales | 5.36 | 6.81 | 19.49 | 16.09 | 2.66 | |
| Enterprise value over EBITDA | 33.82 | 93.42 | 155.36 | 134.72 | 19.7 | |
| EV to operating cash flow | 64.49 | 98.31 | 92.62 | 82.82 | 48.41 | |
| EV to free cash flow | -167.14 | -88.64 | 128.27 | 125.06 | 193.39 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0.02 | |
| Free cash flow yield | -0.01 | -0.01 | 0.01 | 0.01 | 0 | |
| Debt to equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Debt to assets | 0.21 | 0.21 | 0.2 | 0.22 | 0.21 | |
| Net debt to EBITDA | -2.17 | -5.6 | -5.12 | -6.24 | -3.1 | |
| Current ratio | 3.42 | 3.4 | 3.31 | 2.96 | 3.05 | |
| Interest coverage | 73.95 | 41.21 | 78.81 | 106.32 | 101.55 | |
| Income quality | 1 | 10.71 | 2.81 | 3.16 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0.95 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.02 | 0.06 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Capex to operating cash flow | -1.39 | -2.11 | -0.28 | -0.34 | -0.75 | |
| Capex to revenue | -0.12 | -0.15 | -0.06 | -0.07 | -0.04 | |
| Capex to depreciation | -2.96 | -3.33 | -1.4 | -1.85 | -1.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.92K | 2.09K | 2.01K | 1.92K | 7.86K | |
| ROIC | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | |
| Return on tangible assets | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Graham Net | 1.58K | 1.35K | 493.84 | 386.99 | 1.36K | |
| Working capital | 160.96B | 153.85B | 153.74B | 151.37B | 151.69B | |
| Tangible asset value | 332.36B | 334.49B | 342B | 341.99B | 345.48B | |
| Net current asset value | 131.36B | 123.23B | 132.53B | 129B | 127.07B | |
| Invested capital | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 24.76B | 22B | 21.34B | 25.57B | 26.39B | |
| Average inventory | 39.39B | 38.82B | 35.96B | 35.67B | 39.86B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 57.65 | 47.63 | 43.43 | 56.63 | 60.59 | |
| Days of inventory on hand | 103.77 | 108.47 | 91.95 | 79.01 | 98.1 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.56 | 1.89 | 2.07 | 1.59 | 1.49 | |
| Inventory turnover | 0.87 | 0.83 | 0.98 | 1.14 | 0.92 | |
| ROE | 0.02 | 0 | 0.02 | 0.02 | 0.02 | |
| Capex per share | -316.09 | -361.27 | -42.41 | -53.2 | -129.64 |
Frequently Asked Questions
What is Dongwha Pharm.Co.,Ltd stock symbol ?
Dongwha Pharm.Co.,Ltd is a US stock and trading under the symbol 000020.KS
What is Dongwha Pharm.Co.,Ltd stock quote today ?
Dongwha Pharm.Co.,Ltd stock price is $8400 today.
Is Dongwha Pharm.Co.,Ltd stock public?
Yes, Dongwha Pharm.Co.,Ltd is a publicly traded company.
Company Profile
- Volume Average 106.22K
- Market Capitalization 243.02B
- Employee 736
- Headquarters Seoul,US
- IPO Date 2000-01-04
-
Website
https://www.dong-wha.co.kr 
Dongwha Pharm Co., Ltd. manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and teeth, hepatic protector, nutrient, tonic, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company was founded in 1897 and is based in Seoul, South Korea.
